The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Abramson Cancer Center at Penn Medicine100 enrolled

Overview

The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC). Patients scheduled to undergo surgical intervention will have blood samples obtained to test for CTCs. Presence of CTCs will be compared to final pathologic diagnosis based on surgical specimens to assess the sensitivity of using CTCs alone to make a definitive diagnosis.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Non-small Cell Lung Cancer (NSCLC)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Clinical diagnosis of stage I NSCLC a. Only patients with a pathologically confirmed NSCLC will be retained for data analysis b. Should pathologic diagnosis reveal a more advanced stage, these subjects will remain in the study 2. 18 years of age 3. Ability to read and sign informed consent 4. Both men and women and members of all races and ethnic groups are eligible for this trial. Exclusion Criteria: 1. Prior cancer diagnosis, excluding previously treated non-melanoma skin cancer 2. Prior or ongoing treatment of the clinically diagnosed cancer

Locations (1)

Abramson Cancer Center of the University of Pennsylvania

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes